Contribute Try STAT+ Today

Bankrupt microbiome-testing startup uBiome, once valued at $600 million by Silicon Valley investors, preliminarily sold its patents at auction to a DNA-testing outfit called Psomagen for less than 1% of the company’s original value on Monday, a person with direct knowledge of the matter told STAT.

Psomagen is a genetic sequencing company that sells personal DNA tests including a gut health test, according to its website. A subsidiary of South Korean biotech Macrogen, the company has at least 25 U.S. employees, all based in Maryland, according to LinkedIn. On Monday, Psomagen offered $7 million for uBiome’s patents portfolio and related intellectual property, according to the source and public bankruptcy documents. No other bidders came forward with a competing offer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy